Antibody formulations
AssigneeGenentech, Inc.
InventorsAjay Deshmukh, Joumana Zeid, Thomas M. Scherer
Life of this patent
Estimating the term…
Abstract
Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations.
Claims66
A formulation comprising an anti-IL13 antibody, wherein the concentration of antibody in the formulation is at least 100 mg/mL and the viscosity of the formulation is less than 15 centipoise (cP) at 25° C.
A formulation comprising an anti-IL13 antibody in a histidine acetate buffer, pH 5.4 to 6.0, wherein the histidine acetate concentration in the buffer is between 5 mM and 40 mM and wherein the concentration of antibody in the formulation is at least 100 mg/mL.
A formulation comprising an antiIL-13 antibody having extended stability, wherein the antibody concentration is at least 100 mg/mL and the viscosity is less than 15 centipoise (cP) at 25° C.
A formulation comprising an anti-IL13 antibody having extended stability in 20 mM histidine acetate buffer, pH 5.7, 175 mM sucrose, 0.03% polysorbate 20, wherein the concentration of antibody in the formulation is 125 mg/mL and the viscosity of the formulation is less than 15 centipoise (cP) at 25° C., and wherein the anti-IL13 antibody comprises three heavy chain CDRs, CDR-H1 having the amino acid sequence of SEQ ID NO.:
- 1, CDR-H2 having the amino acid sequence of SEQ ID NO.:
- 2, and CDR-H3 having the amino acid sequence of SEQ ID NO.:
- 3, and three light chain CDRs, CDR-L1 having the amino acid sequence of SEQ ID NO.:
- 4, CDR-L2 having the amino acid sequence of SEQ ID NO.:
- 5, and CDR-L3 having the amino acid sequence of SEQ ID NO.:
- 6.
A formulation comprising an anti-IL13 antibody having extended stability in 20 mM histidine acetate buffer, pH 5.7, 175 mM sucrose, 0.03% polysorbate 20, wherein the concentration of antibody in the formulation is 150 mg/mL and the viscosity of the formulation is less than 15 centipoise (cP) at 25° C., and wherein the anti-IL13 antibody comprises three heavy chain CDRs, CDR-H1 having the amino acid sequence of SEQ ID NO.:
- 1, CDR-H2 having the amino acid sequence of SEQ ID NO.:
- 2, and CDR-H3 having the amino acid sequence of SEQ ID NO.:
- 3, and three light chain CDRs, CDR-L1 having the amino acid sequence of SEQ ID NO.:
- 4, CDR-L2 having the amino acid sequence of SEQ ID NO.:
- 5, and CDR-L3 having the amino acid sequence of SEQ ID NO.:
- 6.
(canceled)
Dependencies are inferred from the claim text.